Answers are grounded in this paper and cite their sources.
HER2 amplification detection assays are widely used as companion diagnostic tools for Herceptin targeted therapy on Breast and Gastric cancer patients. Current tests approved for clinical use are in general IHC or FISH-based and could only be used on tissue samples. This requires tissue processing to generate FFPE slices and subjective results determination by pathologists. Here we report the development and validation of a digital PCR based assay to be used to determine the status of HER2 amplification in both tissue and plasma samples. Interestingly, we have found that the status of HER2 may change during therapy and disease development, supporting the necessity of a liquid biopsy assay for HER2 amplification.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: